Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients

Withdrawn

• Conditions: Acute Coronary Syndrome; Acute Myocardial Infarction

• Registration Number: NCT01678339
• Lead Sponsor: AstraZeneca

Brief Summary

Thi is an observational, non interventional, cohort analysis by using administrative databases (drugs treatment, laboratory and diagnostic tests, specialist visits and hospitalizations) of Sicilia region to evaluate treatment patterns of patients after Acute Coronary Syndrome (ACS) event.

Detailed Description

HEALTH-DB ACS

Study Timeline

• Study First Submitted: 2012-08-23
• Study First Submitted QC: 2012-08-31
• Study Start: 2012-09
• Study First Posted: 2012-09-05
• Status Verified: 2012-10
• Last Update Submitted: 2012-10-02
• Last Update Posted: 2012-10-03
• Study Completion: 2012-12

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Subjects discharged alive from hospitalization for ACS

Exclusion Criteria

• All patients that don't have a continuative presence as beneficiaries of the region between January 1st, 2007 and December 31st 2011 will be excluded from analysis.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The chronological analysis of the requirements will allow the identification of potential therapeutic combinations or substitutions.	up to 2 years
Adherence to treatment will be calculated in the manner suggested by the literature and used in previous publications. Different methods of assessment will, however, used in order to study the variability of results. The analysis will be conducted over	up to 2 years
The diagnostic path for each patient included in the analysis will be described by using all prescription for laboratory test (eg. total cholesterol, LDL cholesterol) and/or diagnostics tests (eg. electrocardiogram) during the observation period.	up to 2 years
The drugs treatment path will be described by using all prescriptions of antihypertensive drugs, lipid-lowering drugs and antiplatelet drugs during the observation period.	up to 2 years

Trial Locations

Locations (1)

Research Site; 🇮🇹 Palermo, Italy